SPARC signs pact with Bioprojet
To acquire exclusive rights for drug to treat auto-immune diseases
Sun Pharma Advanced Research Company (SPARC) has entered a…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
SPARC
SPARC enters into licensing deal with CMS to develop and commercialise products
The initial term of the agreement shall be 20 years from the date of first commercial sale of each product in the territory and…
SPARC gets orphan drug designation for Phenobarbital from US FDA
Orphan Drug Designation will grant seven years of US market exclusivity upon approval of Phenobarbital for the treatment of…
SPARC’s Rs 250-crore rights issue to open on March 28
The proceeds of the issue will be utilised for meeting costs related to pharma research and development
US FDA reverses NDA nod for Sun Pharma’s anti epileptic drug
SPARC had earlier received a final approval from US FDA in March 2015 for this product
Sun Pharma Advanced Research Company…
SPARC receives CRL from US FDA for Latanoprost NDA
The product will be manufactured at SPIL’s Halol facility
Sun Pharma Advanced Research Company (SPARC) announced that the US Food…
SPARC licenses Xelpros to Sun Pharma
In December 2014, the US FDA had issued a Complete Response letter (CRL) to SPARC for its New Drug Application (NDA) for…